Identification of Molecular Subtypes and a Prognostic Signature Based on m6A/m5C/m1A-Related Genes in Lung adenocarcinoma
Authors:
Preprint
- 29 November 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Lung adenocarcinoma (LUAD) is the most common histological type of lung cancer and has high incidence and mortality rates worldwide. Increasing evidence suggests that RNA modifications involving m6A, m5C, and m1A play a vital part in tumorigenesis, drug resistance and immunotherapy. However, there is no reliable model according to m6A/m5C/m1A-related genes to predict the patients’ prognosis in LUAD. We obtained patient data from The Cancer Genome Atlas (TCGA) and captured m6A/m5C/m1A-related genes from the GeneCards database. The “ConsensusClusterPlus” R package was used to generate molecular subtypes based on m6A/m5C/m1A-related genes obtained by differential expression analysis and univariate Cox analysis. We constructed a prognostic signature consisting of six genes (SNHG12, PABPC1, IGF2BP1, FOXM1, CBFA2T3, and CASC8), which was identified as an independent prognostic factor. Higher risk scores were associated with poorer overall survival and increased expression of human leukocyte antigen and immune checkpoints. The relationships between m6A/m5C/m1A regulated gene subsets and risk model and immune cell infiltration were analyzed using estimate, CIBERSORT, TIMER, ssGSEA algorithms and exclusion (TIDE). The tumour stemness indices (TSIs) were also compared based on m6A/m5C/m1A -related molecular subtypes and the risk signature. Based on the risk signature, various analyses were conducted including stratification, somatic mutation, nomogram construction, chemotherapeutic response prediction, and small-molecule drug prediction. In conclusion, we constructed a six-gene prognostic signature that could be useful for prognostication in LUAD patients and designing personalized treatments, which could provide new versions of personalized management for these patients.Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- DNA methylation in lung cancer patients: Opening a "window of life" under precision medicineBiomedicine & Pharmacotherapy, 2021
- Smoking-associated upregulation of CBX3 suppresses ARHGAP24 expression to activate Rac1 signaling and promote tumor progression in lung adenocarcinomaOncogene, 2021
- LIN28B-AS1-IGF2BP1 binding promotes hepatocellular carcinoma cell progressionCell Death & Disease, 2020
- PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR/C5a axis from the tumor microenvironmentNeoplasia, 2019
- Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 2019
- Genome-wide identification of transcription factors that are critical to non-small cell lung cancerCancer Letters, 2018
- Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translationNature Cell Biology, 2018
- Insulin-like growth factor 2 mRNA-binding proteins (IGF2BPs): post-transcriptional drivers of cancer progression?Cellular and Molecular Life Sciences, 2012
- Loss of MTG16a (CBFA2T3), a novel rDNA repressor, leads to increased ribogenesis and disruption of breast acinar morphogenesisJournal of Cellular and Molecular Medicine, 2010
- FoxM1 dances with mitosisNature Cell Biology, 2005